David Geldmacher

Dr. David Geldmacher, a leading neurologist and director of Cognitive and Behavioral Neurology at UAB, shares groundbreaking insights on Alzheimer's treatment. He discusses the impact of FDA-approved anti-amyloid therapies and their potential to alter disease progression. The importance of holistic diagnosis, personalized treatment strategies for agitation and sleep disturbances, and the critical role of caregivers in navigating care are also highlighted. Geldmacher emphasizes ongoing research's role in shaping the future of Alzheimer’s care, benefiting both patients and families.